Altimmune, Inc. Aktie News

LOS ANGELES , May 23, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Class Period: December 1, 2023 – April 26, 2024 Lead Plaintiff Deadline: July 5, 2024 If you wish to serve as lead plaintiff of the ...

NEW YORK , May 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between December 1, 2023 and April 26, 2024.

NEW YORK , May 22, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "Class Period"), of the important July 5, 2024 lead plaintiff deadline . SO WHAT: If you purchased Altimmune securities during the Class Period you may be entitled ...

NEW YORK , May 22, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) and certain officers. The class action, filed in the United States District Court for the District of Maryland, Southern Division, and docketed under 24-cv-01315, is on behalf of a class consisting of all persons and enti...

NEW YORK--(BUSINESS WIRE)---- $ALT #ALT--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”), of the important July 5, 2024 lead plaintiff deadline. SO WHAT: If you purchased Altimmune securities during the Class Period you may be entitled ...

NEW YORK , May 21, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

LOS ANGELES , May 20, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT).

SAN DIEGO--(BUSINESS WIRE)---- $ALT #ALT--Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug.